🚀Enjoy a 7-Day Free Trial Until Jul 19, 2024!

PY

Pyxis Oncology IncNASDAQ PYXS Stock Report

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is PYXS undervalued compared to its fair value?

The fair value of PYXS stock is hidden USD. Relative to the market price of 3.03 USD Pyxis Oncology Inc is hidden.

Pyxis Oncology, Inc. engages in the development of antibody therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 73 full-time employees. The company went IPO on 2021-10-08. The fir...[More about valuation]

Pyxis Oncology Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.175 $B

Price:

3.03 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.063

FINANCIALS

Pyxis Oncology financial for reporting period

Income Statement

0.016 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0056 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0033 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.016 B 100%
0.016 B 97%
-0.0056 B -35%
-0.0033 B -20%

Balance Sheet

0.22 B
0.18 B

Financial Position Analysis

Assets

0.22 B
Current Assets
0.17 B
Total non-current assets
0.048 B

Total current liabilities
0.014 B
Total non-current liabilities
0.022 B

Cash Flow Statement

-0.021 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.021 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Pyxis Oncology fundamental analysis for trailing twelve months (TTM)

Profitability score


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-39 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-210 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-31 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is PYXS attractive for investment based on fundamental analysis?

PYXS stock rating is hidden. Pyxis Oncology is a hidden by Eyestock methodology.

Get PYXS Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-358

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

7.563

Debt / Equity ratio:

ROE:

-39

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

PYXS analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for PYXS to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Pyxis Oncology Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Pyxis Oncology Inc dividends

PYXS dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About PYXS stock

About the company Pyxis Oncology Inc

Market cap $B

0.175

Dividend yield

Shares outstanding

34.95873 B

Pyxis Oncology, Inc. engages in the development of antibody therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 73 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. The firm leverages its fully integrated research, development, and commercial capabilities to build a diversified portfolio of next-generation therapeutics. The firm's therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The firm has developed a broad portfolio of novel antibody-drug conjugate (ADC), immuno-oncology (IO), product candidates, and monoclonal antibody (mAb), preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. The firm's product pipelines are PYX-201 and PYX-106.

PYXS profile

  • Ticker

    PYXS

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    08 October 2021

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    73

  • City

    Cambridge

  • Address

    35 Cambridge Park Drive, Suite 1555

  • Cusip

    747324101